Technology Platforms
In Vitro/In Vivo Pharmacology
Disease-Relevant Pharmacology to Strengthen Translational Confidence
Axcelead provides integrated in vitro and in vivo pharmacology services designed to maximize disease relevance and translational predictability throughout drug discovery and early development.
Our core focus extends beyond data generation to building a coherent evidence chain that connects human-relevant biology to clinically interpretable outcomes.
We start with in vitro systems that capture disease-specific phenotypes, including patient-derived and tissue-based platforms, and carry the same biological hypothesis into in vivo studies anchored by clinically used endpoints. By aligning models, endpoints, and analyses under a single decision framework, we help reduce translational uncertainty and support confident decisions from target validation to translational proof of concept.
Our pharmacology platform supports a broad range of therapeutic areas, including CNS, oncology, immunology, cardiovascular / kidney, metabolic, and bone / joint diseases, with a shared focus on biological relevance, mechanistic clarity, and clinical interpretability.
In Vitro Pharmacology: Human-Relevant and Translational Assay Platforms
In vitro pharmacology plays a critical role in understanding mechanism of action, disease biology, and human relevance before advancing into animal studies. Axcelead offers a comprehensive portfolio of cell-based and ex vivo assays, ranging from foundational screening systems to advanced patient-derived and tissue-based platforms that capture disease-specific phenotypes.
Assay Portfolio across Therapeutic Areas
Our in vitro capabilities address key biological questions across multiple disease areas:
- CNS: Neuronal function and network activity (MEA), axonal injury, neurite outgrowth, protein aggregation, and myelination-related assays.
- Immunology / Immuno-Oncology: Human immune cell function including T cell and NK cell killing, exhaustion, ADCC, CDC, MLR, and immune cell differentiation.
- Oncology: Tumor cell proliferation and survival, immune-tumor interactions using patient-derived tumor cells and organoids, immune-tumor co-culture systems, drug resistance mechanisms, and combination effects.
- Cardiovascular / Kidney / Metabolic: Fibrosis, hypertrophy, lipid and glucose metabolism, and functional readouts using disease-relevant primary cells.
- Bone / Joint / Pain: Osteoblast and osteoclast differentiation, mineralization, and pain-related cellular mechanisms.
Key Strengths
- Patient-derived and human tissue-based models: Fresh clinical samples, tumor organoids, and ex vivo tissue systems that preserve disease-specific characteristics.
- Custom assay development: Tailored assay design aligned with client-specific hypotheses, including customized cellular models and approaches such as genome editing.
- Integrated data analysis: Omics, spatial transcriptomics, multiplex immunohistochemistry (IHC), and AI-assisted image analysis for deep mechanistic insight.
These platforms enable early identification of biologically relevant drug candidates and inform rational progression into in vivo studies.
In Vivo Pharmacology: Clinically Anchored and Predictive Disease Models
In vivo pharmacology is essential for translating experimental findings into clinically meaningful outcomes. Axcelead’s in vivo services are built around disease-relevant animal models, clinically used endpoints, and modality-ready evaluation systems that strengthen the link between preclinical data and human biology.
All in vivo studies are conducted in AAALAC International-accredited facilities where applicable, ensuring high standards of animal welfare, data integrity, and scientific reliability.
Broad Disease Coverage with Model Depth
We support in vivo studies across a wide range of disease areas, selecting or developing models based on pathophysiological relevance rather than convenience.
- CNS: Evaluations anchored to clinical endpoints such as EEG, CMAP, microdialysis, and non-invasive imaging, linking functional readouts to disease phenotypes (e.g., 6‑OHDA/LPC/EAE contexts).
- Oncology: Humanized (PBMC/HSC) models, plus xenograft/PDX/orthotopic studies to assess antitumor activity and immune mechanisms (IVIS/CT/Echo supported).
- Immunology: Disease-relevant models (e.g., IBD/MS/RA/psoriasis/GvHD) with translational biomarkers and histopathology for quantitative immune-modulation readouts.
- Cardiovascular / Kidney / Metabolic: Proprietary and established models, including MC4R knockout (KO) for metabolic/MASH research and AXCC for Alport syndrome, combined with Echo/CT, GFR, and biomarkers for functional assessment.
- Pain: Nerve-injury and chemotherapy-induced neuropathy paradigms with AI-assisted behavioral analytics and clinically aligned endpoints for phenotype quantification.
- Bone / Joint: Osteoporosis (OVX/ORX) and osteoarthritis (MIA) models using functional, imaging, and histological endpoints to support translation.
Key Strengths
- Clinically anchored endpoints: Translational readouts such as EEG, CMAP, GFR, Echo and CT to align preclinical outcomes with clinical assessment.
- Proprietary and customized disease models: Original genetically modified models (e.g., MC4R KO for metabolic/MASH research and AXCC for Alport syndrome) and rapid development of new models tailored to client needs.
- Advanced evaluation technologies: Non-invasive imaging, AI-based behavioral analysis, and functional biomarkers that capture subtle disease phenotypes.
- Modality-ready platforms: Support for small molecules, antibodies, nucleic acids, DDS, and cell therapies, including humanized and immunosuppressed models.
Our in vivo platforms are designed not only to demonstrate efficacy, but also to generate data that inform clinical strategy and de-risk development.
Axcelead’s Integrated Pharmacology Solution
From standard assays to fully customized research platforms, Axcelead offers a holistic pharmacology solution that integrates in vitro and in vivo studies for maximum translational impact.
Partner with Axcelead to build pharmacology strategies grounded in disease relevance, human biology, and clinical insight.
